• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种QS21加CpG佐剂的三价单纯疱疹病毒2型疫苗和三价单纯疱疹病毒2型信使核糖核酸疫苗可诱导强烈的免疫反应，预防单纯疱疹病毒2型感染，并对小鼠的单纯疱疹病毒1型感染产生交叉保护作用。

A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cross-Protect Against HSV-1 Infection in Mice.

作者信息

Cao Han, Zhang Xiaolong, Cheng Jishuai, Li Yang, Luan Ning, Hu Jingping, Liang Bingyan, Zhang Haihao, Gao Dandan, Lei Zhentao, Yao Yufeng, Liu Cunbao

机构信息

Institute of Medical Biology, Peking Union Medical College, Chinese Academy of Medical Sciences, Kunming 650118, China.

Laboratory Animal Department, Kunming Medical University, Kunming 650500, China.

出版信息

Vaccines (Basel). 2025 May 6;13(5):497. doi: 10.3390/vaccines13050497.

DOI:10.3390/vaccines13050497
PMID:40432109
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12115586/
Abstract

BACKGROUND

HSV-2 infection continues to be a significant global health concern, as there are no approved vaccines despite numerous attempts at development.

METHODS

This study explored the immunogenicity and protective efficacy of aluminum- or QS21 + CpG-adjuvanted trivalent HSV-2 vaccines and a trivalent HSV-2 mRNA vaccine incorporating the gC2, gD2, and gE2 antigens.

RESULTS

Our results demonstrated that the QS21 + CpG-adjuvanted subunit vaccine and mRNA vaccines successfully induced robust antigen-specific humoral and cellular immune responses and provided significant protection against both HSV-2 and HSV-1 infection. These vaccines showed remarkable efficiency in reducing the viral load and preventing clinical symptoms in mice, highlighting their potential for clinical application. Conversely, the aluminum-adjuvanted vaccine exhibited limited effectiveness, emphasizing the superiority of the QS21 + CpG-adjuvanted and mRNA vaccines.

CONCLUSIONS

These findings provide valuable insights for the continued development of effective HSV vaccines and suggest promising strategies for preventing both HSV-2 and HSV-1 infection.

摘要

背景

尽管经过多次研发尝试，但仍未批准用于单纯疱疹病毒2型（HSV-2）感染的疫苗，因此HSV-2感染仍是一个重大的全球健康问题。

方法

本研究探讨了铝佐剂或QS21 + CpG佐剂的三价HSV-2疫苗以及包含gC2、gD2和gE2抗原的三价HSV-2 mRNA疫苗的免疫原性和保护效果。

结果

我们的结果表明，QS21 + CpG佐剂的亚单位疫苗和mRNA疫苗成功诱导了强大的抗原特异性体液免疫和细胞免疫反应，并对HSV-2和HSV-1感染提供了显著保护。这些疫苗在降低小鼠病毒载量和预防临床症状方面显示出显著效果，突出了它们的临床应用潜力。相反，铝佐剂疫苗的有效性有限，凸显了QS21 + CpG佐剂和mRNA疫苗的优越性。

结论

这些发现为继续研发有效的HSV疫苗提供了有价值的见解，并为预防HSV-2和HSV-1感染提出了有前景的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/df4070e697da/vaccines-13-00497-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/be7964b6f24f/vaccines-13-00497-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/d8390f6fa949/vaccines-13-00497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/b1039768ae3d/vaccines-13-00497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/0a639306092b/vaccines-13-00497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/33cb974e09f8/vaccines-13-00497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/0f459b9f53e8/vaccines-13-00497-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/df4070e697da/vaccines-13-00497-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/be7964b6f24f/vaccines-13-00497-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/d8390f6fa949/vaccines-13-00497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/b1039768ae3d/vaccines-13-00497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/0a639306092b/vaccines-13-00497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/33cb974e09f8/vaccines-13-00497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/0f459b9f53e8/vaccines-13-00497-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93e/12115586/df4070e697da/vaccines-13-00497-g007.jpg

相似文献

1
A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cross-Protect Against HSV-1 Infection in Mice.一种QS21加CpG佐剂的三价单纯疱疹病毒2型疫苗和三价单纯疱疹病毒2型信使核糖核酸疫苗可诱导强烈的免疫反应，预防单纯疱疹病毒2型感染，并对小鼠的单纯疱疹病毒1型感染产生交叉保护作用。
Vaccines (Basel). 2025 May 6;13(5):497. doi: 10.3390/vaccines13050497.
2
Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.阻断单纯疱疹病毒 2 糖蛋白 E 的免疫逃逸作用以增强三价亚单位抗原疫苗治疗生殖器疱疹的疗效。
J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.
3
Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.佐以稳定乳剂和Toll样受体9激动剂的预防性单纯疱疹病毒2型（HSV-2）疫苗可诱导强烈的HSV-2特异性细胞介导免疫反应，预防症状性疾病，并减少潜伏病毒库。
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02257-16. Print 2017 May 1.
4
A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1.三价单纯疱疹病毒 2 型 gC2、gD2、gE2 核苷修饰信使核糖核酸-LNP 疫苗在小鼠中提供针对生殖器和非生殖器单纯疱疹病毒 1 型感染的出色保护，与源自单纯疱疹病毒 1 型的相同抗原相当。
Viruses. 2023 Jun 30;15(7):1483. doi: 10.3390/v15071483.
5
Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.含有糖蛋白C、D和E的2型单纯疱疹病毒三价蛋白疫苗可保护豚鼠免受HSV-1生殖器感染。
Hum Vaccin Immunother. 2020 Sep 1;16(9):2109-2113. doi: 10.1080/21645515.2020.1749509. Epub 2020 Apr 29.
6
An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.一种单纯疱疹病毒2型三价疫苗在恒河猴中具有免疫原性，在豚鼠中高度有效。
PLoS Pathog. 2017 Jan 19;13(1):e1006141. doi: 10.1371/journal.ppat.1006141. eCollection 2017 Jan.
7
A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.一种双模态单纯疱疹病毒2型疫苗，通过使用糖蛋白C和D亚基抗原诱导强效抗体反应以及包含衣壳和被膜蛋白的腺病毒载体作为T细胞免疫原，用于预防生殖器疱疹。
J Virol. 2015 Aug;89(16):8497-509. doi: 10.1128/JVI.01089-15. Epub 2015 Jun 3.
8
A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.三价亚单位抗原糖蛋白疫苗作为免疫疗法治疗豚鼠生殖器感染模型中的生殖器疱疹。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2785-2793. doi: 10.1080/21645515.2017.1323604. Epub 2017 May 8.
9
A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.一种三价 gC2/gD2/gE2 疫苗可诱导产生针对单纯疱疹病毒的抗体反应，其阻断 gC2 免疫逃逸结构域的能力优于自然感染。
Vaccine. 2019 Jan 21;37(4):664-669. doi: 10.1016/j.vaccine.2018.11.076. Epub 2018 Dec 12.
10
Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.单纯疱疹病毒2型（HSV - 2）糖蛋白C和D亚基抗原疫苗对HSV - 1血清阳性豚鼠生殖器HSV - 2感染的保护作用。
J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13. Epub 2013 Nov 27.

引用本文的文献

1
A QS21+ CpG-Adjuvanted Rabies Virus G Subunit Vaccine Elicits Superior Humoral and Moderate Cellular Immunity.一种QS21加CpG佐剂的狂犬病病毒G亚单位疫苗可引发卓越的体液免疫和适度的细胞免疫。
Vaccines (Basel). 2025 Aug 21;13(8):887. doi: 10.3390/vaccines13080887.

本文引用的文献

1
Linking vaccine adjuvant mechanisms of action to function.将疫苗佐剂的作用机制与功能相联系。
Sci Immunol. 2025 Feb 14;10(104):eado5937. doi: 10.1126/sciimmunol.ado5937.
2
Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses.2020年全球及区域单纯疱疹病毒感染和生殖器溃疡疾病的估计发病率和患病率：数学建模分析
Sex Transm Infect. 2025 May 19;101(4):214-223. doi: 10.1136/sextrans-2024-056307.
3
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture.
通过植物细胞培养生产的疫苗佐剂QS-21的化学和生物学特性
iScience. 2024 Jan 26;27(3):109006. doi: 10.1016/j.isci.2024.109006. eCollection 2024 Mar 15.
4
Understanding Herpes Simplex Virus Type 1 Versus Herpes Simplex Virus Type 2 Encephalitis After Neurosurgery: A Case Series and Literature Review.神经外科手术后1型单纯疱疹病毒与2型单纯疱疹病毒脑炎的认识：病例系列及文献综述
Surg Infect (Larchmt). 2023 Sep;24(7):583-587. doi: 10.1089/sur.2023.030. Epub 2023 Aug 2.
5
Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs.新型佐剂 S-540956 联合 HSV-2 糖蛋白 D 作为治疗性疫苗在豚鼠中给药时可靶向淋巴结并减少生殖器复发和 HSV-2 DNA 的阴道脱落。
Viruses. 2023 May 10;15(5):1148. doi: 10.3390/v15051148.
6
Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants.阐明核仁素作为基于核酸的佐剂的细胞表面受体的作用。
NPJ Vaccines. 2022 Oct 6;7(1):115. doi: 10.1038/s41541-022-00541-6.
7
Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine.可电离脂质纳米颗粒增强了水痘带状疱疹病毒糖蛋白E亚单位疫苗中CpG ODNs和QS21的协同佐剂作用。
Pharmaceutics. 2022 Apr 30;14(5):973. doi: 10.3390/pharmaceutics14050973.
8
Evaluation of HSV-2 gE Binding to IgG-Fc and Application for Vaccine Development.单纯疱疹病毒2型糖蛋白E与IgG-Fc结合的评估及其在疫苗开发中的应用
Vaccines (Basel). 2022 Jan 25;10(2):184. doi: 10.3390/vaccines10020184.
9
Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy.水痘-带状疱疹病毒糖蛋白E羧基末端突变对mRNA疫苗效力的影响。
Vaccines (Basel). 2021 Dec 7;9(12):1440. doi: 10.3390/vaccines9121440.
10
Pathogenesis and virulence of herpes simplex virus.单纯疱疹病毒的发病机制与毒力。
Virulence. 2021 Dec;12(1):2670-2702. doi: 10.1080/21505594.2021.1982373.